Fat metabolism research fragment
AOD-9604.
4 vendors · CA$50–60
Modified C-terminal fragment of human growth hormone (hGH 177–191). Researched for adipose-tissue mechanisms; not approved for human therapeutic use.
Live vendor register · grouped by strength
Every vendor. Cheapest per mg first, kits listed separately.
AOD-9604 · price per mg
4 listings · unflagged vendors first · Listings data last updated October 2026
Best price per mg: Peptide Warehouse 5 mg at CA$10.00/mg. Kits go lower — CA$6.60/mg, sold only in multi-vial packs.
5 mg
3 listings02
PepsupVID-PEPSUP · €34.99 · duties on delivery
5 mg
99%
No COA published (mfr claim 99%+)
In stock
NL dispatch · PostNL Tracked 2–5 business days
CA$11.20/mg
CA$56
Kits · multi-vial packs, price per vial
01
QSC PeptidesVID-QSC-PEPT · Kit of 10 · CA stock
5 mgkit of 10
99%
HPLC · MS · Janoshik
In stock
2–8 days
CA$6.60/mg
CA$33≈ CA$330 per kit
Same research area
Similar compounds.
GH secretagogue research
Ipamorelin
Synthetic pentapeptide described in 1998 by Novo Nordisk researchers as a selective ghrelin/GH-secretagogue receptor agonist; researched for growth-hormone release. Not approved for human therapeutic use.
5 vendorsCA$24–100
GHRH analogue research
CJC-1295
GHRH(1-29) analogue developed by ConjuChem; the DAC form binds albumin and persists for days, the no-DAC form (Mod GRF 1-29) is short-acting. Researched for GH/IGF-1 stimulation; not approved for human therapeutic use.
5 vendorsCA$43–86
GLP-1 receptor agonist research
Semaglutide
GLP-1 receptor agonist, FDA- and EMA-approved as Ozempic, Wegovy and Rybelsus. Research-vial semaglutide is a different, unapproved product, not made or reviewed as those medicines, and not for human use.
2 vendorsCA$80
GIP/GLP-1 dual agonist research
Tirzepatide
Dual GIP/GLP-1 receptor agonist, FDA- and EMA-approved as Mounjaro and Zepbound. Research-vial tirzepatide is a different, unapproved product, not made or reviewed as those medicines, and not for human use.
2 vendorsCA$145
Triple hormone agonist research
Retatrutide
Investigational triple GIP/GLP-1/glucagon receptor agonist (LY3437943) developed by Eli Lilly and studied in Phase 3 trials; not approved as a medicine anywhere and not for human therapeutic use.
2 vendorsCA$112
Amylin analogue research
Cagrilintide
Long-acting amylin-receptor agonist (AM833 / NNC0174-0833) developed by Novo Nordisk, studied alone and in the CagriSema combination; not approved as a medicine anywhere and not for human therapeutic use.
1 vendorCA$32per vial · kits only
Long-form research guide
Weight Loss Research. Mechanism + protocols + safety.
Lipolysis, GH secretagogues, and adipose tissue modulation in obesity models
Open the long-form guide for AOD-9604 →